CBDA is a derivative of CBGA and the precursor to the well known cannabinoid CBD. Over the last decade scientists have found that CBDA has a very similar chemical structure to that of nonsteroidal anti-inflammatory drugs (NSAIDs) and thus has shown promise in treating pain due to inflammation by inhibiting COX-2 receptors in the brain that register pain. CBDA has also been shown to help regulate the over release of serotonin that causes severe nausea and vomiting in patients receiving chemotherapy, and while more thorough research is needed these results are very promising.

Delta 9 THC is the primary compound found in the resinous glands of a cannabis plant, and is directly responsible for psychoactive effects. It mirrors the body’s naturally occurring cannabinoids and attaches to these receptors to alter and enhance sensory perception. THC can create a feeling of euphoria by enhancing dopamine levels in the brain. The amount of THC in a cannabis product can vary widely based on the method of consumption and the strain at the source of that product. The high that is produced is often enhanced by the “entourage effect” which is a combination of multiple cannabinoids in conjunction with various terpenes and individual body chemistry.

THCV sets itself apart from its cousin THC with its distinct lack of psychoactive effects. THCV also acts as an allosteric modulator for Delta-9-THC thus reducing its psychoactivity. It has been found to be helpful as an appetite suppressant, neuroprotectant and glycemic control in type 2 diabetics.